. 2022 Feb 12;11(2):661–682. doi: 10.1007/s40121-022-00591-2

Table 2.

In vitro activity of β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-nonsusceptible P. aeruginosa isolates

Agent	Study	Database, location, year	n	MIC₅₀	MIC₉₀	MIC range	CLSI			EUCAST
Agent	Study	Database, location, year	n	MIC₅₀	MIC₉₀	MIC range	%S	%I	%R	%S	%R
Ceftolozane–tazobactam	Gill et al. 2021 [74]	ERACE-PA, USA, 2019–21	149	1	16	NR	85	4	11	85	15
	Gill et al. 2021 [74]	ERACE-PA, EUR, 2019–21	324	1	> 64	NR	65	6	29	85	35
	Karlowsky et al. 2020 [78]	SMART, USA, 2015–17	229	NR	NR	NR	67.5	NR	NR	NR	NR
Ceftazidime–avibactam	Gill et al. 2021 [74]	ERACE-PA, USA, 2019–21	149	2	16	NR	87	–	13	87	13
Ceftazidime–avibactam	Gill et al. 2021 [74]	ERACE-PA, EUR, 2019–21	324	4	32	NR	79	–	21	79	21
Imipenem–relebactam	Karlowsky et al. 2020 [78]	SMART, USA, 2015–17	229	2	> 32	≤ 0.06 to > 32	70.3	8.1	21.6	NR	NR
Imipenem–relebactam	Lob et al. 2020 [79]	SMART, EUR, 2015–17	469	NR	NR	NR	62.2	NR	NR	74.4	25.6
Cefiderocol	Iregui et al. 2020 [80]	Iregui et al., USA, 2017	269	0.25	0.5	≤ 0.03 to 8	99.6	NR	NR	NR	NR
Cefiderocol	Iregui et al. 2020 [80]	Iregui et al., USA, 2013–14	130	0.5	1	≤ 0.03 to 4	100	0	0	100	0

EUR Europe, CLSI Clinical and Laboratory Standards Institute, EUCAST European Committee on Antimicrobial Susceptibility Testing, MIC minimum inhibitory concentration, S susceptible, I intermediate, R resistant, NR not reported [51–53]